Neuphoria Therapeutics Inc.
NEUP
$4.67
-$0.17-3.51%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 60.63% | 49.83% | 28.21% | 6.13% | -20.10% |
| Total Depreciation and Amortization | 0.00% | 19.94% | 49.97% | 36.63% | 24.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -154.97% | -574.70% | -165.31% | -134.73% | -129.03% |
| Change in Net Operating Assets | -101.47% | -99.14% | -61.64% | 1,044.42% | 221.27% |
| Cash from Operations | 23.30% | 14.93% | 7.12% | -13.63% | -36.41% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -10.42% | -117.26% | -35,350.00% | -298.36% | -194.94% |
| Cash from Investing | -10.42% | -117.26% | -35,350.00% | -300.15% | -195.73% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 5.87% | 320.30% | 313.36% | 159.76% | 134.20% |
| Issuance of Common Stock | -55.97% | -68.18% | 27.16% | -15.71% | -43.74% |
| Repurchase of Common Stock | 99.96% | -- | -- | 3.33% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 758.90% | 298.02% | 1,252.73% | 265.47% | 119.73% |
| Cash from Financing | 21.96% | 438.59% | 262.38% | 111.39% | 6.69% |
| Foreign Exchange rate Adjustments | 453.11% | 302.58% | 309.18% | 199.26% | 76.30% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 49.96% | 101.71% | 107.18% | 42.16% | -62.41% |
